SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

<h4>Unlabelled</h4>SPL7013 Gel (VivaGel(®)) is a microbicide in development for prevention of HIV and HSV. This clinical study assessed retention and duration of antiviral activity following vaginal administration of 3% SPL7013 Gel in healthy women. Participants received 5 single doses o...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Clare F Price, David Tyssen, Secondo Sonza, Ashley Davie, Sonya Evans, Gareth R Lewis, Shirley Xia, Tim Spelman, Peter Hodsman, Thomas R Moench, Andrew Humberstone, Jeremy R A Paull, Gilda Tachedjian
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2011
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/bdfe8b68946e44cf931a6d338a6ecc77
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/bdfe8b68946e44cf931a6d338a6ecc77

Documents similaires